Oncolytic capacity of attenuated replicative Semliki Forest virus in human melanoma xenografts in severe combined immunodeficient mice

Cancer Research

Volumn 66, Issue 14, 2006, Pages 7185-7194

  Vähä Koskela, Markus J V ^a,b   Kallio, Janne P ^b,c   Jansson, Linda C ^a   Heikkilä, Jari E ^a   Zakhartchenko, Vasily A ^a   Kallajoki, Markku A ^b   Kähäri, Veli Matti ^b,c   Hinkkanen, Ari E ^a  

^a ÅBO AKADEMI UNIVERSITY   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; ONCOLYTIC VIRUS; VIRUS PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLOGICAL THERAPY; CANCER CELL CULTURE; COMBINED IMMUNODEFICIENCY; CONNECTIVE TISSUE; CONTROLLED STUDY; CYTOLYSIS; EXPLANT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SEMLIKI FOREST ALPHAVIRUS; TUMOR CELL; TUMOR RESISTANCE; TUMOR XENOGRAFT; VIROTHERAPY; VIRUS INFECTION; VIRUS RESISTANCE; VIRUS STRAIN;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CRICETINAE; GREEN FLUORESCENT PROTEINS; HUMANS; MELANOMA; MICE; MICE, SCID; ONCOLYTIC VIROTHERAPY; SEMLIKI FOREST VIRUS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33746917920     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2214     Document Type: Article

References (50)

1. Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF. Regression of Hodgkins disease after measles. Lancet 1981;1:1112.
2. Challis GB, Stam HJ. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol 1990;29:545-50.
3. Bowles AP, Jr., Perkins E. Long-term remission of malignant brain tumors after intracranial infection: a report of four cases. Neurosurgery 1999;44:636-42.
4. Kleef R, Jonas WB, Knogler W, Stenzinger W. Fever, cancer incidence, and spontaneous remissions. Neuroimmunomodulation 2001;9:55-64.
5. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-73.
6. Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002;20:2251-66.
7. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002;62:6070-9.
8. Immonen A, Vapalahti M, Tyynelä K, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004;10:967-72.
9. Strauss JH, Strauss EG. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 1994;58:491-562.
10. Fazakerley JK, Pathak S, Scallan M, Amor S, Dyson H. Replication of the A7(74) strain of Semliki Forest virus is restricted in neurons. Virology 1993;195:627-37.
11. Tuittila MT, Santagati MG, Röyttä M, Määttä JA, Hinkkanen AE. Replicase complex genes of Semliki Forest virus confer lethal neurovirulence. J Virol 2000;74:4579-89.
12. Vähä-Koskela MJ, Tuittila MT, Nygårdas PT, et al. A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus. J Neurovirol 2003;9:1-15.
13. Oliver KR, Scallan MF, Dyson H, Fazakerley JK. Susceptibility to a neurotropic virus and its changing distribution in the developing brain is a function of CNS maturity. J Neurovirol 1997;3:38-48.
14. Atkins GJ, Carter J, Sheahan BJ. Effect of alphavirus infection on mouse embryos. Infect Immun 1982;38:1285-90.
15. Glasgow GM, McGee MM, Tarbatt CJ, Mooney DA, Sheahan BJ, Atkins GJ. The Semliki Forest virus vector induces p53-independent apoptosis. J Gen Virol 1998;79:2405-10.
16. Molife R, Hancock BW. Adjuvant therapy of malignant melanoma. Crit Rev Oncol Hematol 2002;44:81-102.
17. Ahonen M, Ala-Aho R, Baker AH, et al. Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. Mol Ther 2002;5:705-15.
18. Simbulan-Rosenthal CM, Rosenthal DS, Iyer S, Boulares AH, Smulson ME. Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis. J Biol Chem 1998;273:13703-12.
19. Ubol S, Park S, Budihardjo I, et al. Temporal changes in chromatin, intracellular calcium, and poly(ADP-ribose) polymerase during Sindbis virus-induced apoptosis of neuroblastoma cells. J Virol 1996;70:2215-20.
20. Taimen P, Kallajoki M. NuMA and nuclear lamins behave differently in Fas-mediated apoptosis. J Cell Sci 2003;116:571-83.
21. Nargi-Aizenman JL, Simbulan-Rosenthal CM, Kelly TA, Smulson ME, Griffin DE. Rapid activation of poly(ADP-ribose) polymerase contributes to Sindbis virus and staurosporine-induced apoptotic cell death. Virology 2002;293:164-71.
22. Amor S, Scallan MF, Morris MM, Dyson H, Fazakerley JK. Role of immune responses in protection and pathogenesis during Semliki Forest virus encephalitis. J Gen Virol 1996;77:281-91.
23. Abend M. Reasons to reconsider the significance of apoptosis for cancer therapy. Int J Radiat Biol 2003;79:427-41.
24. Holubec H, Payne CM, Bernstein H, et al. Assessment of apoptosis by immunohistochemical markers compared to cellular morphology in ex vivo-stressed colonic mucosa. J Histochem Cytochem 2005;53:229-35.
25. Pusztai R, Gould KA, Smith H. Infection patterns in mice of an a virulent and virulent strain of Semliki Forest virus. Br J Exp Pathol 1971;52:669-77.
26. Sauthoff H, Hu J, Maca C, et al. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther 2003;14:425-33.
27. Shafren DR, Au GG, Nguyen T, et al. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res 2004;10:53-60.
28. Tseng JC, Hurtado A, Yee H, et al. Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res 2004;64:6684-92.
29. Wang KS, Kuhn RJ, Strauss EG, Ou S, Strauss JH. High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J Virol 1992;66:4992-5001.
30. Smit JM, Waarts BL, Kimata K, Klimstra WB, Bittman R, Wilschut J. Adaptation of alphaviruses to heparan sulfate: interaction of Sindbis and Semliki forest viruses with liposomes containing lipid-conjugated heparin. J Virol 2002;76:10128-37.
31. Klimstra WB, Nangle EM, Smith MS, Yurochko AD, Ryman KD. DC-SIGN and L-SIGN can act as attachment receptors for alphaviruses and distinguish between mosquito cell- and mammalian cell-derived viruses. J Virol 2003;77:12022-32.
32. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778-809.
33. Morris A, Tomkins PT, Maudsley DJ, Blackman M. Infection of cultured m urine brain cells by Semliki Forest virus: effects of interferon-α β on viral replication, viral antigen display, major histocompatibility complex antigen display, and lysis by cytotoxic T lymphocytes. J Gen Virol 1987;68:99-106.
34. Landis H, Simon-Jodicke A, Kioti A, et al. Human MxA protein confers resistance to Semliki Forest virus and inhibits the amplification of a Semliki Forest virus-based replicon in the absence of viral structural proteins. J Virol 1998;72:1516-22.
35. Scallan MF, Allsopp TE, Fazakerley JK. bcl-2 acts early to restrict Semliki Forest virus replication and delays virus-induced programmed cell death. J Virol 1997;71:1583-90.
36. Grandgirard D, Studer E, Monney L, et al. Alpha viruses induce apoptosis in Bcl-2-overexpressing cells: evidence for a caspase-mediated, proteolytic inactivation of Bcl-2. EMBO J 1998;17:1268-78.
37. Smyth JW, Fleeton MN, Sheahan BJ, Atkins GJ. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector. Gene Ther 2005;12:147-59.
38. Abou El Hassan MA, van der Meulen-Muileman I, Abbas S, Kruyt FA. Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J Virol 2004;78:12243-51.
39. Chi S, Kitanaka C, Noguchi K, et al. Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. Oncogene 1999;18:2281-90.
40. Lustig S, Halevy M, Ben-Nathan D, Rice CM, Kobiler D. The role of host immunocompetence in neuro-invasion of Sindbis virus. Arch Virol 1999;144:1159-71.
41. Lundström K, Abenavoli A, Malgaroli A, Ehrengruber MU. Novel Semliki Forest virus vectors with reduced cytotoxicity and temperature sensitivity for long-term enhancement of transgene expression. Mol Ther 2003;7:202-9.
42. Kopf-Maier P, Kesienbach LI. The interaction between host-supplied connective tissue and xenografted human tumor cells. Anticancer Res 1990;10:161-71.
43. Bilbao R, Bustos M, Alzuguren P, et al. A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds. Gene Ther 2000;7:1824-32.
44. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res 2002;62:1063-8.
45. Harrison D, Sauthoff H, Heitner S, Jagirdar J, Rom WN, Hay JG. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved-deletion of the viral EIb-19-kD gene increases the viral oncolytic effect. Hum Gene Ther 2001;12:1323-32.
46. Grote D, Russell SJ, Cornu TI, et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001;97:3746-54.
47. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002;62:4656-62.
48. Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999;5:881-7.
49. Liu R, Martuza RL, Rabkin SD. Intracarotid delivery of oncolytic HSV vector G47Δ to metastatic breast cancer in the brain. Gene Ther 2005;12:647-54.
50. Shinozaki K, Ebert O, Kournioti C, Tai YS, Woo SL. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther 2004;9:368-76.